Maggie is the recipient of a 2-year, $300,000 Mallinckrodt Challenge Grant for her study “Targeting Podocyte Dysfunctional Ryanodine Receptor to Treat Nephrotic Syndrome.”
The overall goals of this proposal are to determine the molecular mechanisms underlying increased podocyte endoplasmic reticulum (ER) calcium efflux under ER stress. The proposed study could lead to a significant leap forward in the treatment of nephrotic syndrome/focal segmental glomerulosclerosis associated with podocyte ER dysfunction in a highly targeted manner.
The grant is provided through a partnership between Mallinckrodt Pharmaceuticals and Washington University School of Medicine, which funds promising research projects reviewed by a committee composed of leaders from both institutions. The challenge grants fund laboratory research that is deemed likely to have future medical applications. Faculty with funded projects will have access to additional resources and services provided by the Mallinckrodt, including analytical chemistry tools and expertise, drug formulation support, and resources for navigating regulatory requirements for drug development.